2025 Guidance
| Sales | $5.6 - $6.0 billion (8% - 10% constant currency growth) |
| TAVR | $4.1 - $4.4 billion (5% - 7% constant currency growth) |
| TMTT | $500 - $530 million (50% - 60% constant currency growth) |
| Surgical | $970 million - $1.05 billion (mid-single digit constant currency growth) |
| FX Impact on Sales | ~$100 million unfavorable (~2pt downside to reported growth) |
| Adjusted Gross Profit Margin | 78% - 79% |
| Adjusted Operating Margin | 27% - 28% |
| Tax Rate | 15% - 18% |
| Adjusted EPS | $2.40 - $2.50 |
| Diluted Shares Outstanding | 585 – 595 million |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.